Hypophosphatemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypophosphatemia. 16 active patents protecting 1 drugs from 0+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
16
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypophosphatemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypophosphatemia. Each bar = one year. Y-axis scaled to peak year (8 patents).

3
27
8
28
1
30
4
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rayaldee
CALCIFEDIOL
 — 16 65 — 2027-02-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9943530 Rayaldee method of use 80 2027-02-02
11801253 Rayaldee method of use 76 2030-09-07
9925147 Rayaldee method of use 75 2028-04-25
8778373 Rayaldee method of use 75 2028-04-25
8207149 Rayaldee method of use 75 2028-04-25
11154509 Rayaldee method of use 75 2028-04-25
9408858 Rayaldee method of use 75 2028-04-25
9498486 Rayaldee method of use 75 2028-04-25
8426391 Rayaldee method of use 75 2028-08-27
8906410 Rayaldee formulation 60 2027-02-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10357502 Rayaldee formulation 42 2034-03-14
9861644 Rayaldee formulation 42 2034-03-14
10300078 Rayaldee formulation 42 2034-03-14
11253528 Rayaldee formulation 50 2034-03-14
8361488 Rayaldee formulation 55 2028-07-19
10213442 Rayaldee formulation 60 2027-02-02
8906410 Rayaldee formulation 60 2027-02-02
8426391 Rayaldee method of use 75 2028-08-27
11154509 Rayaldee method of use 75 2028-04-25
8778373 Rayaldee method of use 75 2028-04-25

Related